300109 Boai NKY Medical
- 12.82
- -0.10-0.77%
Boai NKY Medical News
Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Boai Nky Medical (300109.SZ): Executives Zou Xiaowen and Li Shegang plan to reduce their holdings by a total of no more than 0.2495 million shares.
Boai NKY Medical (300109.SZ) announced on September 18th that Mr. Zou Xiaowen, a senior management personnel, held 667,904 shares of the company's stock as of the announcement date, accounting for 0.14% of the total share capital of the company. Mr. Zou plans to reduce his shareholding of the company by no more than 166,976 shares (not exceeding 0.03% of the total share capital) through centralized bidding or block trading within 3 months after 15 trading days from the date of the announcement (from October 17, 2024 to January 16, 2025, excluding the blackout period). He currently holds 330,000 shares of the company's stock, accounting for
New open source: 2024 semi-annual report
New Open Source: 2024 Semi-Annual Report Summary
Boai Nky Medical (300109.SZ): The net income in the first half of the year was 0.213 billion yuan, a year-on-year decrease of 18.79%.
On August 29th, boai nky medical (300109.SZ) released its interim report for the first half of 2024. During the reporting period, the total operating revenue was RMB 0.735 billion, a decrease of 5.68% year-on-year. The net income attributable to shareholders of the listed company was RMB 0.213 billion, a decrease of 18.79% year-on-year. After deducting non-recurring gains and losses, the net income attributable to shareholders of the listed company was RMB 0.218 billion, a decrease of 15.36% year-on-year. The basic earnings per share were RMB 0.45.
Boai Nky Medical (300109.SZ) released its semi-annual performance, with a net income of 0.213 billion yuan, a decrease of 18.79%.
boai nky medical (300109.SZ) released its 2024 interim report, with revenue of 0.735 billion yuan...
We Think Boai NKY Medical Holdings (SZSE:300109) Can Stay On Top Of Its Debt
As of August 9th, the number of shareholders for Boai Nky Medical (300109.SZ) was approximately 23,700 when combined.
Boai Nky Medical (300109.SZ) stated on the investor interaction platform on August 13th that the number of shareholders of the company as of August 9th was about 23,700 after merging.
As of the end of July, the shareholder count of Boai Nky Medical (300109.SZ) is approximately 22,800 households.
Boai Nky Medical (300109.SZ) stated on the investors' interactive platform on August 6th that as of the end of July, the number of shareholders of the company was about 22,800.
Earnings Growth of 36% Over 1 Year Hasn't Been Enough to Translate Into Positive Returns for Boai NKY Medical Holdings (SZSE:300109) Shareholders
As of July 20, the number of shareholders of Boai Nky Medical (300109.SZ) was approximately 22,700.
On July 24, Gelunhui reported that as of July 20, the number of shareholders in Boai Nky Medical (300109.SZ) was approximately 22,700.
As of July 10th, the number of shareholders of Boai Nky Medical (300109.SZ) has merged to about 23,100.
On July 16th, Gelunhui reported that as of July 10th, the total number of shareholders of Boai Nky Medical (300109.SZ) was around 23,100 on the investor interaction platform.
Boai Nky Medical (300109.SZ): Sales of vinyl ether products are relatively low and are still being developed in the market.
On July 8th, Gelunhui reported that an investor asked a question on the investor interaction platform to Boai Nky Medical (300109.SZ) about the progress of ethylene ether products in 2023, besides PVP and Eurazeo. The company replied that the sales volume of ethylene ether products is small and is still being developed in the market.
Boai Nky Medical (300109.SZ): The annualized production capacity of PVP is about 20,000 tons.
On July 3rd, Gelonhui reported that Boai Nky Medical (Stock Code: 300109) stated on the investor interaction platform that the annual production capacity of PVP is about 20,000 tons, and the specific capacity can be adjusted in a timely manner according to sales.
As of the end of June, the total number of shareholders of Boai Nky Medical (300109.SZ) was about 23,900.
As of the end of June, the total number of shareholders for Boai Nky Medical (300109.SZ) was approximately 23,900 according to the company's investor communication platform.
Boai Nky Medical (300109.SZ): Currently there are no plans for research and development or operation in synthetic biology.
On June 25th, Glon Hui reported that Boai Nky Medical (300109.SZ) expressed on its investor interaction platform that the company and Huadao will explore new drug models for CAR-T and other cell drugs based on Huadao's self-developed cell drug full industry chain technology. There are currently no synthetic biology research and operation plans.
New open source (300109.SZ): 2023 equity distribution 10 transfers 3 free 2 transfers 10 yuan share registration date June 6
Gelonghui, May 29丨New Open Source (300109.SZ) announced that the company's 2023 equity distribution plan is to distribute 2 shares for every 10 shares and distribute RMB 10 in cash (tax included) to all shareholders based on the company's current total share capital of 323,501,837 shares. At the same time, 3 shares were transferred to all shareholders for every 10 shares using the capital reserve fund. The share registration date for this equity distribution is June 6, 2024, and the ex-dividend date is June 7, 2024.
Is Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Recent Stock Performance Tethered To Its Strong Fundamentals?
Many Still Looking Away From Boai NKY Medical Holdings Ltd. (SZSE:300109)
New Open Source (300109.SZ): Net profit of 121 million yuan in the first quarter increased 1.17% year over year
On April 26, Ge Longhui (300109.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 395 million yuan, up 8.73% year on year; net profit attributable to shareholders of listed companies was 121 million yuan, up 1.17% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 126 million yuan, up 6.21% year on year; basic earnings per share were 0.38 yuan.
Analysis
Price Target
No Data
No Data